New inhalable therapy strongly combats IPF lung scarring in mice
A novel inhalable therapy has shown promise for treating idiopathic pulmonary fibrosis (IPF) by outperforming an approved oral medicine in a mouse study. The new treatment, called VB-RT NPs, consists of lipid nanoparticles loaded with two medicines, verteporfin and berbamine, designed to disrupt both the mechanical stiffness and biochemical…
